The European Commission has approved the VidPrevtyn Beta COVID-19 vaccine as a booster for individuals who are at least 18.
The vaccine is the first next-gen protein-based adjuvanted COVID-19 booster to win European approval.
Sanofi (Nasdaq:SNY) developed the vaccine based on the beta variant using GSK’s (NYSE:GSK) pandemic adjuvant.
After announcing the news, Sanofi shares were up 1.45% to $43.97 in early afternoon trading. GSK shares were up 2.42% to $33.21.
VidPrevtyn Beta is a monovalent, recombinant-protein vaccine developed by Sanofi, modeled on the Beta variant and including GSK’s pandemic adjuvant. The vaccine uses recombinant-protein technology found in Sanofi’s seasonal flu vaccines.
In July, GSK and Sanofi announced that their adjuvanted bivalent version of its vaccine was 72% efficacious against omicron in adults in a Phase 3 study.
GSK and Sanofi noted that the vaccine performed well in registrational trials when the omi…